European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 134, Issue 2 , Pages 143-146 , October 2007

Breast cancer and climacteric complaints: Weighing up risks of hormone therapy against quality of life

  • Henk R. Franke

      Affiliations

    • Department of Obstetrics and Gynecology, Medisch Spectrum Twente Hospital Group, Enschede, The Netherlands
    • Corresponding Author InformationCorresponding author at: Department of Obstetrics and Gynecology, Medisch Spectrum Twente Hospital Group, PO Box 50000, 7500 KA Enschede, The Netherlands. Tel.: +31 534872000; fax: +31 534339571.
    • ,
  • Monique M.A. Brood-van Zanten

      Affiliations

    • Department of Obstetrics and Gynecology, VU Medical Center, Amsterdam, The Netherlands
    • ,
  • Curt W. Burger

      Affiliations

    • Department of Obstetrics and Gynecology, Erasmus Medical Center, Rotterdam, The Netherlands
    • ,
  • Marius J. van der Mooren

      Affiliations

    • Department of Obstetrics and Gynecology, VU Medical Center, Amsterdam, The Netherlands
    • ,
  • Peter Kenemans

      Affiliations

    • Department of Obstetrics and Gynecology, VU Medical Center, Amsterdam, The Netherlands

Received 29 October 2006 ,Revised 23 April 2007 ,Accepted 10 May 2007.

References 

  1. van der Mooren MJ, Kenemans P. Postmenopausal hormone therapy: impact on menopause-related symptoms, chronic disease and quality of life. Drugs. 2004;64:821–836[review]
  2. Kenemans P. Postmenopausal hormone therapy and breast cancer: what is the problem?. Maturitas. 2005;51:75–82
  3. van der Mooren MJ, Brood-van Zanten MMA, C.C.M. Beerendonk CCM, The HS, Franke HR. NVOG Richtlijn no. 69: Hormoontherapie van klachten in het climacterium en de postmenopauze; 2005.
  4. Endogenous Hormones and Breast Cancer Collaborative Group . Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies.. J Natl Cancer Inst. 2002;94:606–616
  5. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst. 2004;96:218–228
  6. Harvey JA, Bovbjerg VE. Quantitative assessment of mammographic breast density: relationship with breast cancer risk. Radiology. 2004;230:29–41
  7. Kenemans P, Speroff L. International Tibolone Consensus Group. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas. 2005;51:21–28
  8. Armstrong K, Schwartz JS, Randall T, Rubin SC, Weber B. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. J Clin Oncol. 2004;22:1045–1054
  9. Rebbeck TR, Friebel T, Wagner T, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: The PROSE Study Group. J Clin Oncol. 2005;23:7804–7810
  10. Hickey M, Saunders CM, Stuckey BG. Management of menopausal symptoms in patients with breast cancer: an evidence-based approach. Lancet Oncol. 2005;9:687–695
  11. Biglia N, Cozzarella M, Cacciari F, et al. Menopause after breast cancer: a survey on breast cancer survivors. Maturitas. 2003;45:29–38
  12. Marsden J, Whitehead M, A’Hern R, Baum M, Sacks N. Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible?. Fertil Steril. 2000;73:292–299
  13. Col NF, Hirota LK, Orr RK, Erban JK, Wong JB, Lau J. Hormone replacement therapy after breast cancer: a systematic review and quantitative assessment of risk. J Clin Oncol. 2001;19:2357–2363[review]
  14. Holmberg L, Anderson H. HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer–is it safe?), a randomised comparison: trial stopped. Lancet. 2004;363:453–455
  15. von Schoultz E, Rutqvist LE. Stockholm Breast Cancer Study Group. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst. 2005;97:533–535
  16. Kubista E. Behandlung klimakterischer Symptome nack Brustkrebs mit Liviel—Die LIBERATE-Studie. J Menopause. 2003;10:16–19
  17. Kroiss R, Fentiman IS, Helmond FA, Rymer J, Foidart JM, Bundred N, et al. The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial. BJOG. 2005;112:228–233
  18. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med. 2001;344:276–285[review]

PII: S0301-2115(07)00225-4

doi: 10.1016/j.ejogrb.2007.05.002

European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 134, Issue 2 , Pages 143-146 , October 2007

Article Tools